Handelsbanken Fonder AB Acquires 5,300 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Handelsbanken Fonder AB boosted its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 3.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 139,800 shares of the company’s stock after purchasing an additional 5,300 shares during the period. Handelsbanken Fonder AB owned approximately 0.47% of Bicycle Therapeutics worth $2,528,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in Bicycle Therapeutics by 489.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock worth $72,000 after purchasing an additional 3,322 shares during the last quarter. Woodstock Corp lifted its stake in Bicycle Therapeutics by 4.5% in the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock worth $388,000 after purchasing an additional 926 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Bicycle Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after purchasing an additional 1,706 shares during the last quarter. Polar Capital Holdings Plc lifted its stake in Bicycle Therapeutics by 33.2% in the third quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock worth $20,321,000 after purchasing an additional 252,000 shares during the last quarter. Finally, RA Capital Management L.P. bought a new stake in Bicycle Therapeutics in the third quarter worth $16,072,000. 86.15% of the stock is owned by institutional investors.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total transaction of $75,191.98. Following the completion of the transaction, the chief executive officer now directly owns 387,270 shares in the company, valued at $9,220,898.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 5,312 shares of company stock valued at $126,139. 10.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on BCYC. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. HC Wainwright lowered their price objective on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, February 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.86.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $22.73 on Friday. The stock’s 50 day simple moving average is $23.95 and its two-hundred day simple moving average is $19.34. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.08 and a current ratio of 8.08. The stock has a market cap of $682.81 million, a price-to-earnings ratio of -4.43 and a beta of 0.89. Bicycle Therapeutics plc has a fifty-two week low of $12.54 and a fifty-two week high of $28.91.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.07. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $11.68 million. Bicycle Therapeutics had a negative return on equity of 57.80% and a negative net margin of 669.72%. As a group, analysts expect that Bicycle Therapeutics plc will post -5.2 earnings per share for the current fiscal year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.